ID   KML1
AC   CVCL_4J73
DR   Wikidata; Q54900122
RX   DOI=10.1159/000415049;
RX   Patent=US5132222;
RX   PubMed=3091508;
CC   Doubling time: 24 hours (PubMed=3091508).
CC   Derived from site: In situ; Lymph node; UBERON=UBERON_0000027.
CC   Breed/subspecies: MRL/lpr.
DI   NCIt; C21602; Mouse lymphoma
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
SX   Female
AG   4M
CA   Cancer cell line
DT   Created: 22-09-15; Last updated: 29-06-23; Version: 5
//
RX   DOI=10.1159/000415049;
RA   Kanai Y., Katagiri T., Mori S., Kanai Y.;
RT   "Establishment and function of an MRL/Mp-lpr/lpr lymphoma line with
RT   null cell properties: its roles for anti-DNA antibody production in
RT   vitro.";
RL   (In) Cellular, molecular, genetic approaches to immunodiagnosis and immunotherapy. 8th International conference on labeled antibodies, Tokyo, November 1985; Kano K., Mori S., Sugisaki T., Torisu M. (eds.); pp.283-288; Karger; Basel (1988).
//
RX   Patent=US5132222;
RA   Kanai Y., Awaya A.;
RT   "Established cell line, KML1-7, which produces B-cell differentiation
RT   factor (BCDF).";
RL   Patent number US5132222, 21-Jul-1992.
//
RX   PubMed=3091508; DOI=10.1159/000234114;
RA   Kanai Y., Katagiri T., Mori S., Kubota T.;
RT   "An established MRL/Mp-lpr/lpr cell line with null cell properties
RT   produces a B cell differentiation factor(s) that promotes
RT   anti-single-stranded DNA antibody production in MRL spleen cell
RT   culture.";
RL   Int. Arch. Allergy Appl. Immunol. 81:92-94(1986).
//